ACBM
Acro Biomedical Co., Ltd.0.0007
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
42.03KP/E (TTM)
-Basic EPS (TTM)
-0.25Dividend Yield
0%Recent Filings
10-Q
8-K
CEO transition at Acro Biomedical
Acro Biomedical Co., Ltd. announced the resignation of Pao-Chi Chu as director, chairman, and CEO on August 14, 2025, effective upon successor appointment, with no disagreements cited. The board immediately appointed Yu-Ting Su as director, chairman, and CEO that day. Su brings biotech expertise from roles at BioSpring and BioSeed. This leadership shift promises continuity in operations.
10-Q
Q2 FY2025 results
Acro Biomedical posted no revenue for Q2 FY2025 ended June 30, 2025, matching last year, while operating expenses climbed to $13,614 from $9,086 y/y, driving an operating loss of $13,614 up 50% y/y (derived). Net loss widened to $15,562 from $10,143 y/y, with the $5,419 gap mainly from higher imputed interest on related-party advances at $1,948 versus $1,057. YTD through June 30, 2025, net loss reached $25,863 on $22,548 operating expenses, up from $21,395 last year, fully reconciling to 60,042,000 diluted shares with no anti-dilution. Cash dwindled to $26 after $116,515 operating outflow offset by $116,065 related-party funding, leaving $241,653 due to affiliates and a $317,520 stockholders' deficit. No capex means free cash flow mirrors operating cash. Thin liquidity persists. Stock trades on Pink Limited Market with no market makers.
10-K
FY2024 results
Acro Biomedical posted a slim FY2024 net loss of $42,000 on zero revenue, a sharp improvement from 2023's $8.8 million shortfall driven by $8.1 million in amortized stock-based compensation for a failed cordyceps chicken feed project that wrapped up mid-year. No sales materialized in Q4 2024 or any quarter, extending a revenue drought since late 2022, while operating expenses dwindled to $38,000 amid inactivity. Cash stayed nominal at $476, propped by $37,000 in minority stockholder advances covering bare-bones operations. No dividends, buybacks, or capex emerged. Yet funding remains elusive. Political instability in Hong Kong threatens any sales rebound.
10-Q
Q1 FY2025 results
Acro Biomedical posted no revenue for Q1 FY2025 ended March 31, 2025, mirroring last year while trimming operating expenses to $8,934 from $10,298—a 13.3% y/y drop (derived)—yielding a narrower operating loss of $8,934 versus $10,298. Net loss eased to $10,301 from $11,252, with the $951 gap mainly from higher related-party interest at $1,367 versus $954. Cash dwindled to $251 after $22,531 in operating outflows, offset by $22,306 in stockholder advances; no capex means free cash flow matches operating cash. Stockholders' deficit deepened slightly to $303,906 amid ongoing reliance on related-party funding. No marketable products emerged from prior R&D. Controls remain weak. Liquidity hangs by a thread.
AACB
Artius II Acquisition Inc.
10.31+0.00
ADIA
Adia Nutrition, Inc.
0.07-0.00
AFJK
Aimei Health Technology Co., Lt
26.96-3.55
CSLMF
CSLM Acquisition Corp.
3.14+0.54
HAIAF
Healthcare AI Acquisition Corp.
12.74+0.00
PACH
Pioneer Acquisition I Corp
10.11+0.01
TACH
Titan Acquisition Corp.
10.24-0.01
TDAC
Translational Development Acqui
10.42+0.00
VACH
Voyager Acquisition Corp
10.57+0.00
WELNF
Integrated Wellness Acquisition
12.21+0.00